| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Spotlight Stock Market: Market Notice 132/26 - Information regarding the rights issue from CHOSA Oncology AB | 1 | Cision News | ||
| Mo | The Board of Directors of Chosa Oncology AB resolves on a rights issue of units of approximately SEK 2.5 million fully covered by pre-subscription commitments | 1 | Cision News | ||
| CHOSA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 09.11. | CHOSA ONCOLOGY AB: CHOSA's ESMO 2026 Expert Meeting Highlights the Unmet Need for Personalized Platinum Therapy in Lung Cancer | 1 | Cision News | ||
| 04.11. | Chosa Oncology AB: CHOSA enters into an agreement with a CLIA-certified laboratory partner for Platin-DRP in the USA - first revenue expected summer 2027 | 534 | PR Newswire | CHOSA enters into an agreement with a CLIA-certified laboratory partner for Platin-DRP in the USA - first revenue expected summer 2027
COPENHAGEN, Denmark, Nov. 4, 2026 /PRNewswire/ -- CHOSA Oncology... ► Artikel lesen | |
| 08.10. | CHOSA ONCOLOGY AB: CHOSA receives 94 tumour samples from US patients to validate Platin-DRP in lung cancer chemo-immunotherapy | - | Cision News | ||
| 27.08. | CHOSA ONCOLOGY AB: CHOSA Oncology accelerates value creation by entering into a commercially driven licensing agreement with Aida Oncology | 2 | Cision News | ||
| 15.07. | CHOSA ONCOLOGY AB: Chosa Oncology announces the result of exercise of warrants TO2 | 1 | Cision News | ||
| 13.07. | CHOSA ONCOLOGY AB: Members of executive management participate in the ongoing warrant - exercise ending tomorrow | 1 | Cision News | ||
| 10.07. | CHOSA ONCOLOGY AB: CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP | 1 | Cision News | ||
| 07.07. | Spotlight Stock Market: Market Notice 76/26 - Last day of trading in CHOSA Oncology AB's subscription option CHOSA TO 2 | 1 | Cision News | ||
| 01.07. | CHOSA ONCOLOGY AB: CHOSA Oncology announces commencement of exercise period for TO2 warrants at the fixed price of SEK 0.78 | 2 | Cision News | ||
| 23.06. | CHOSA ONCOLOGY AB: CHOSA Oncology establishes US presence in Boston to support commercialization of Platin-DRP | 1 | Cision News | ||
| 01.06. | CHOSA ONCOLOGY AB: CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers | 4 | Cision News | ||
| 01.06. | CHOSA ONCOLOGY AB: CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study | 1 | Cision News | ||
| 27.05. | Bulletin from the annual general meeting on 27 May 2026 in Chosa Oncology AB | 1 | Cision News |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |